Europe Insulin Delivery Devices Market Size - By Product, By End Use - Regional Forecast, 2025 - 2034

Europe Insulin Delivery Devices Market Size

The Europe insulin delivery devices market was valued at USD 6.5 billion in 2024. The market is expected to grow from USD 7.2 billion in 2025 to USD 17.8 billion in 2034, at a CAGR of 10.6% during the forecast period, according to the latest report published by Global Market Insights Inc.

The Europe insulin delivery device market is witnessing robust growth, stimulated by the growing prevalence of diabetes across Europe, rising geriatric population, ongoing innovations in insulin delivery devices, government initiatives and reimbursement policies. Leading companies such as Novo Nordisk, Medtronic, Sanofi, Eli Lilly and Company, and Becton, Dickinson and Company are at the forefront of this industry. These companies sustain their market leadership by consistently innovating insulin delivery device technologies, forming strategic alliances, and leveraging robust international distribution channels to enhance patient care and streamlining diabetes management.
 

The European insulin delivery devices market grew from USD 4.9 billion in 2021 to USD 5.9 billion in 2023. Rising diabetes prevalence, government initiatives, and reimbursement policies stimulating the market expansion in the European region. For instance, according to the International Diabetes Federation, 65.6 million adults aged 20-79 in Europe were living with diabetes in 2024, accounting for 1 in 10 adults across the region. The age-standardized prevalence of diabetes is 8%, projected to rise to 9.4% by 2050. Thus, the growing burden of diabetes is accelerating demand for advanced, efficient insulin delivery devices across Europe.
 

Moreover, the growing geriatric population is a major catalyst for the expansion of the European insulin delivery devices market. As people age, the risk of developing chronic conditions such as Type 2 diabetes increases significantly due to metabolic changes, reduced physical activity, and age-related insulin resistance. For instance, according to the Survey of Health, Ageing and Retirement in Europe (SHARE), the overall prevalence of diabetes among adults aged 50+ across 11 European countries is 21.2%, with 14% diagnosed and 7.2% undiagnosed. Older adults often require consistent and precise insulin therapy, which accelerates the demand for advanced insulin delivery systems, such as insulin pens, pumps, and other devices, further fostering market growth in the region.
 

Insulin delivery devices are specialized medical tools used to administer insulin safely, accurately, and conveniently for individuals with diabetes. These devices are essential for effective diabetes management, helping patients regulate their blood sugar levels when their bodies cannot produce enough insulin on their own.
 

Europe Insulin Delivery Devices Market Trends

• Ongoing innovations in insulin delivery technologies are reshaping diabetes management in Europe by prioritizing discretion, automation, and user control. Ultra-discreet wearable pumps and automated patch pumps are at the forefront of this transformation. These devices are designed to be compact, tubeless, and smartphone-integrated, allowing users to manage insulin delivery with minimal disruption to daily life.
   
• By combining continuous glucose monitoring (CGM), which is estimated to reach USD 47.1 billion by 2034, with intelligent algorithms, these systems offer real-time adjustments and predictive dosing, significantly improving glycemic control and quality of life for users. Under the ultra-discreet category, Tandem Mobi stands out as the smallest durable automated insulin delivery system. It features a 200-unit insulin cartridge, an on-pump button for bolus delivery, and full iPhone control via Tandem’s Control-IQ+ technology. This hybrid closed-loop system predicts and prevents glucose highs and lows, enhancing time-in-range throughout the day.
   
• In the automated patch pump space, ViCentra’s Kaleido 2 is a next-generation device known for its ultra-lightweight, customizable design. It integrates with Diabeloop pumps and Dexcom CGMs, comes with two rechargeable pumps, and offers flexible wearability options either as a patch or via tubing, making it stylish and a highly functional choice for modern diabetes care.
   
• Moreover, manufacturers maintain leadership in the European insulin delivery devices market by consistently investing in innovation, patient-centric design, and strategic partnerships. They focus on developing advanced technologies, such as smart insulin pens, tubeless pumps, and integrated systems with continuous glucose monitoring, to enhance treatment outcomes and user convenience, thereby fostering market growth in the region.
   

Europe Insulin Delivery Devices Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The European market for insulin delivery devices was valued at USD 4.9 billion in 2021. The market size reached USD 5.9 billion in 2023, from USD 5.4 billion in 2022. Based on product, the devices segment accounted for 73.6% of the market share in 2024, primarily due to their technological advancement, long-term usability, and growing preference among patients and healthcare providers. The segment is expected to reach USD 13 billion by 2034, growing with a CAGR of 10.6% during the forecast period. On the other hand, consumables segment is expected to grow with slightly higher CAGR of 10.7%. The growth of this segment is primarily driven by the recurring demand for essential components such as testing strips, pen needles, syringes, and insulin pump consumables.
 

• Consumables in the insulin delivery devices market refer to the essential, disposable components used regularly by individuals with diabetes to monitor and manage their condition. These include testing strips for blood glucose monitoring, pen needles for insulin pens, syringes for direct insulin injection, and insulin pump consumables such as infusion sets and reservoirs. These items are critical for ensuring accurate dosing, maintaining hygiene, and supporting patient comfort and compliance in daily diabetes care.
   
• In Europe, the demand for these consumables is stimulated by the rising prevalence of diabetes, increasing adoption of advanced insulin delivery systems, and growing awareness of self-management. For example, BD Ultra-Fine Pen Needles are known for their comfort and precision, these products are distributed through hospitals, pharmacies, and online platforms, making them accessible across the region.
   
• Their consistent use ensures effective disease management, reduces complications, and improves quality of life for patients. Thus, as technology evolves and patient needs diversify, the market for insulin delivery consumables is expected to grow, with innovation focusing on comfort, accuracy, and integration with digital health platforms.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, Europe insulin delivery devices market is classified into hospitals and clinics, home care, and other end users. The hospitals and clinics segment is expected to reach USD 7.1 billion by 2034.
 

• Hospitals and clinics are central to the growth of the insulin delivery devices market in Europe. These institutions serve as the first point of contact for diabetes diagnosis and treatment, where patients are introduced to insulin therapy and trained on using delivery devices.
   
• The widespread presence of hospitals and clinics across Europe ensures broad access to insulin delivery solutions. Germany leads with over 1,900 hospitals, continually upgrading rural and urban facilities to meet rising patient volumes. This institutional support contributes significantly to the overall volume of insulin devices used.
   
• Thus, as healthcare systems continue to evolve toward more integrated and patient-centric models, the role of hospitals and clinics in supporting insulin delivery will remain vital to market expansion and improved diabetes outcomes.

Looking for region specific data?

Download Free PDF

The Germany insulin delivery devices market was valued at USD 684.4 million and USD 742.6 million in 2021 and 2022, respectively. The market size reached USD 901 million in 2024, growing from USD 811.5 million in 2023.
 

• The Germany market is stimulated by a high diabetes burden and growing awareness among people. For instance, according to the International Diabetes Federation, 6.5 million adults (ages 20-79) in Germany were living with diabetes in 2024. Thus, as the prevalence increases, so does the demand for technologically advanced insulin delivery devices for the management of diabetes.
   
• Moreover, Germany’s National Diabetes Surveillance Program, led by the Robert Koch Institute (RKI), plays a pivotal role in shaping nationwide data-driven healthcare strategies. Thus, such surveillance supports the growth of the Germany insulin delivery device market by highlighting unmet needs, encouraging adoption of advanced technologies, and guiding public health investments.
   

France insulin delivery devices market accounted for USD 637.6 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• France stands out as one of the fastest-growing countries in the European insulin delivery devices market, driven by its diabetes care expenditure, strong regulatory frameworks, and the growing burden of diabetes. According to the International Diabetes Federation, as of 2024, France had approximately 4.1 million adults (ages 20-79) living with diabetes.
   
• Moreover, France ranked among the top 10 countries globally in spending on diabetes care in 2024. Thus, France’s significant investment in diabetes care and its rising diabetic population are fueling strong growth in the France insulin delivery devices market.
   

UK insulin delivery devices market is estimated to grow with a significant CAGR of 11.7% in the Europe market.
 

• The UK is rapidly becoming one of the most dynamic markets in the European insulin delivery devices landscape, driven by its large diabetic population and increasing public awareness of diabetes care.
   
• For instance, as per the data from Diabetes UK, around 4.6 million people in the UK are living with a diabetes diagnosis, with Type 1 diabetes patients requiring lifelong insulin therapy. The country’s National Diabetes Audit reports that nearly all individuals with Type 1 diabetes are prescribed insulin, with increasing uptake of insulin pump therapy and continuous glucose monitoring (CGM) devices.
   
• Thus, with growing awareness and widespread access to therapy, the UK is emerging as a key contributor to innovation and growth in the European insulin delivery devices market.
   

Italy insulin delivery devices market exhibited remarkable growth in 2024.
 

• The National Diabetes Plan laid a robust foundation by ensuring universal access to insulin therapies and promoting integrated care across regional systems. With insulin provided free at the point of care, the demand for advanced delivery solutions such as pens, pumps, and smart dosing systems has surged, prompting manufacturers to innovate and expand within Italy’s publicly funded healthcare landscape.
   
• Further accelerating this momentum, the Italian Medicines Agency (AIFA) approved weekly basal insulin, introducing a transformative shift in insulin administration. By reducing injection frequency from daily to weekly, this advancement significantly enhances patient adherence and creates new opportunities for specialized devices tailored to long-acting formulations.
   
• Together, these developments are reshaping Italy’s insulin delivery ecosystem, fostering innovation and improving outcomes for people living with diabetes.
   

Spain insulin delivery devices market to experience substantial growth across the Europe market in 2024.
 

• Spain is experiencing a significant rise in diabetes among its aging population, stimulated by demographic shifts and lifestyle-related risk factors. As of 2022, there were over 9.4 million older adults in Spain, nearly 20% of the total population, a group at higher risk of developing diabetes.
   
• Therefore, this convergence of aging and chronic disease is prompting Spanish health authorities to strengthen surveillance, prevention, and access to care, including insulin delivery devices, especially in rural and high-risk regions, thereby fostering market growth.
   

Europe Insulin Delivery Devices Market Share

• Leading top 5 players in the Europe insulin delivery devices industry such as Novo Nordisk, Medtronic, Sanofi, Eli Lilly and Company, and Becton, Dickinson and Company, collectively hold market share of 60%. These companies maintain their leadership through a combination of strong research and development, strategic partnerships, and robust distribution networks. Additionally, their focus on patient-centric solutions and digital integration has reinforced their competitive edge.
   
• Innovation is a key differentiator in this market. For instance, Novo Nordisk, has pioneered smart insulin pens such as the NovoPen 6 and NovoPen Echo Plus, which automatically log insulin doses and offer memory functions. These innovations not only improve treatment accuracy but also empower patients to manage their diabetes more effectively.
   
• The European market is witnessing a shift toward smart, connected insulin delivery systems. Insulin pumps are gaining popularity due to their precision and automation, while smart pens are being adopted for their ease of use and data tracking capabilities. Government support through favorable reimbursement policies and national diabetes strategies is further accelerating this trend.
   
• Companies such as BD and Novo Nordisk are setting industry benchmarks through advanced, user-friendly products that align with modern healthcare needs. As digital health continues to shape the future of diabetes care, the market is poised for sustained growth, with innovation and accessibility at its core.
   

Europe Insulin Delivery Devices Market Companies

Prominent players operating in the Europe insulin delivery devices industry are as mentioned below:
 

• B. Braun Melsungen
• Becton, Dickinson and Company
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Gan & Lee Pharmaceuticals
• Haselmeier
• Insulet
• Medtronic
• MicroPort
• Nipro
• Novo Nordisk
• Owen Mumford
• Sanofi
• Tandem Diabetes Care
• Terumo
• ViCentra B.V.
• Wockhardt Ltd.
  
   
• Novo Nordisk

Novo Nordisk stands out in Europe’s insulin delivery landscape through its deep-rooted expertise in diabetes care and its commitment to patient-centric innovation. The company offers a comprehensive range of insulin pens such as the FlexPen, NovoPen, and FlexTouch which are known for their ease of use, precision dosing, and ergonomic design. These devices are widely adopted across Europe due to their reliability and compatibility with various insulin formulations.
 

• Medtronic

Medtronic is a prominent player in the Europe delivery devices market, known for its deep expertise in diabetes care and advanced medical technologies. The company’s strong regional footprint, commitment to innovation, and focus on integrated care solutions have positioned it as a key provider of reliable and effective insulin delivery systems. Through strategic collaborations and technology-driven initiatives, Medtronic continues to enhance access and improve patient outcomes across diverse healthcare landscapes in Europe.
 

• Insulet

Insulet is establishing itself as a prominent innovator in Europe’s insulin delivery devices market through its advanced tubeless insulin pump technology. The company’s flagship product, the Omnipod system, provides a discreet and user-friendly alternative to conventional insulin delivery methods, enhancing patient comfort and simplifying diabetes management.
 

Europe Insulin Delivery Devices Industry News

• In May 2025, Tandem Diabetes Care received CE mark approval for its Tandem Mobi insulin pump, equipped with the advanced Control-IQ+ technology. This regulatory milestone not only validated the device’s safety and performance for the European market but also enabled the company to broaden its geographical footprint, paving the way for expansion across new regions.
   
• In February 2024, Insulet announced it had received CE mark approval under the European Medical Device Regulation for the enhanced compatibility of the Abbott FreeStyle Libre 2 Plus sensor with its Omnipod 5 Automated Insulin Delivery System. This approval, which applies to individuals aged two years and older with type 1 diabetes, strengthens Insulet’s market position by offering a more integrated and user-friendly solution, giving the company a distinct competitive edge in the European diabetes care landscape.
   

The Europe insulin delivery devices research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue of USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Devices
  • Insulin pumps
    • Tubed pumps
    • Tubeless pumps
  • Pens
    • Reusable
    • Disposable
  • Other insulin delivery devices
• Consumables    
  • Testing strips
  • Pen needles
    • Standard
    • Safety
  • Syringes
  • Insulin pumps consumables

Market, By End Use

• Hospitals and clinics
• Home care
• Other end use

The above information is provided for the following countries:

• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Sweden
• Belgium
• Denmark
• Finland
• Norway
• Lithuania
• Latvia
• Estonia
• Russia
• Poland
• Switzerland